We are delighted to announce that Róisín NicAmhlaoibh will join the UK DRI as Chief Innovation and Business Officer, commencing September 2024.
Róisín joins UK DRI with over 20 years’ experience translating research to benefit patients, across government, academic, industry and not-for-profit sectors.
Following post-doctoral studies at UCSF's Comprehensive Cancer Center, Róisín worked in biopharma drug discovery before joining Cancer Research Technology (now Horizons) where she spent 13 years leading the commercialisation of academic discoveries. She has led business development activities within CPRD, the MHRA's real world data centre, at the Rosalind Franklin Institute, Harwell, and with the leading US liquid biopsy company, Guardant Health. She is currently VP of Business Development at Ground Truth Labs, a spin-out from the University of Oxford that develops AI-enabled predictive and prognostic haematoncology tests.
On her appointment to UK DRI, Róisín said:
"I am excited to join UK DRI, at a time of unprecedented activity in the translation of neurodegeneration research, for the benefit of people at risk of, or living with, dementia and other neurodegenerative conditions. UK DRI is a global leader in the field and I look forward to working with the team to advance ground-breaking discoveries to combat these devastating diseases."
UK DRI Director, Prof Siddharthan Chandran, said:
"We are delighted to welcome Róisín to the UK DRI as our new Chief Innovation and Business Officer. Her extensive experience in translating research into tangible benefits for patients, combined with her proven track record in commercialising academic discoveries, makes her the perfect fit for our institute.
Róisín's leadership in various prestigious organisations will be invaluable as we continue to drive forward innovative solutions in dementia research. We are confident that her expertise will significantly advance our mission to improve the lives of those affected by dementia."
Article published: 17 June 2024
